• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Poseida Therapeutics Inc.

    1/13/25 4:05:12 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PSTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)


    Poseida Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    73730P108

    (CUSIP Number)


    Matthew Halbower
    Pentwater Capital Management LP, 1001 10th Avenue South, Suite 216
    Naples, FL, 34102
    239-384-9750

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    01/08/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    73730P108


    1 Name of reporting person

    Pentwater Capital Management LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    IA, PN



    SCHEDULE 13D

    CUSIP No.
    73730P108


    1 Name of reporting person

    Matthew Halbower
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    IN, HC



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.0001 per share
    (b)Name of Issuer:

    Poseida Therapeutics, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO, CALIFORNIA , 92121.
    Item 1 Comment:
    This Amendment No. 3 ("Amendment No. 3") amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission on December 28, 2020 (the "Original Schedule 13D", and the Original Schedule 13D as amended, the "Schedule 13D"). This Amendment No. 3 supplements Items 4 and 6 and amends and restates Item 5(a)-(c), and (e) as set forth below. Capitalized terms used herein and not otherwise defined in this Amendment No. 3 have the meanings set forth in the Schedule 13D.
    Item 4.Purpose of Transaction
     
    Pursuant to the terms of the Pentwater Support Agreement, the Pentwater Funds tendered the shares of Common Stock beneficially owned by them in the Tender Offer. The Tender Offer expired as scheduled at one minute following 11:59 p.m., New York City time, on January 7, 2025. The shares of Common Stock held by the Pentwater Funds were accepted for payment on January 8, 2025. As a result, the Reporting Persons no longer own, beneficially or otherwise, any securities of the Issuer. In addition, on January 8, 2025, following consummation of the Tender Offer, Merger Sub merged with and into the Issuer, with the Issuer being the surviving corporation (the "Merger"). Accordingly, at the effective time of the Merger, the Pentwater Support Agreement terminated pursuant to its terms.
    Item 5.Interest in Securities of the Issuer
    (a)
    See rows (11) and (13) of the cover page to this Schedule 13D for the aggregate number of shares of Common Stock and percentage of shares of Common Stock beneficially owned by each Reporting Person.
    (b)
    See rows (7) through (10) of the cover page to this Schedule 13D for the shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
    (c)
    Except as disclosed in Item 4, there have been no transactions effected by the Reporting Persons during the past sixty (60) days.
    (e)
    January 8, 2025.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    As a result of the closing of the Merger, the Cash Derivative Agreements held by the Pentwater Funds at the time of closing of the Merger settled in accordance with their terms based on the Offer Consideration as defined in the Merger Agreement.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Pentwater Capital Management LP
     
    Signature:/s/ Matthew Halbower
    Name/Title:By: Halbower Holdings, Inc., General Partner, By: Matthew Halbower, Chief Executive Officer
    Date:01/13/2025
     
    Matthew Halbower
     
    Signature:/s/ Matthew Halbower
    Name/Title:By: Halbower Holdings, Inc., General Partner, By: Matthew Halbower, Chief Executive Officer
    Date:01/13/2025
    Get the next $PSTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PSTX

    DatePrice TargetRatingAnalyst
    12/2/2024$10.00Overweight → Neutral
    Piper Sandler
    1/4/2023$15.00Buy
    H.C. Wainwright
    1/7/2022$24.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Poseida Therapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Poseida Therapeutics from Overweight to Neutral and set a new price target of $10.00

      12/2/24 10:07:39 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Poseida Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Poseida Therapeutics with a rating of Buy and set a new price target of $15.00

      1/4/23 7:49:53 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Poseida Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Poseida Therapeutics with a rating of Overweight and set a new price target of $24.00

      1/7/22 8:13:46 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting

      Additional new profiling of patient responses from the optimized lymphodepletion arm (Arm C) show consistent P-BCMA-ALLO1 cellular expansion and persistence across subgroups New preclinical data supports P-CD19CD20-ALLO1's strong anti-cancer profile and the ongoing Phase 1 clinical trial Case study demonstrates reactivation of an autologous Poseida CAR-T therapy with a T-cell engager in patient with relapsed multiple myeloma, highlighting potential of TSCM-based CAR-T therapies to deliver a strong anti-myeloma response with long-term remission and CAR-T cell persistence SAN DIEGO, Dec. 9, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage allogeneic cell therapy

      12/9/24 12:00:00 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

      Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's Pharmaceuticals Division SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, auto

      11/26/24 1:10:00 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Malin Life Sciences Holdings Ltd closing all direct ownership in the company (SEC Form 4)

      4 - Poseida Therapeutics, Inc. (0001661460) (Issuer)

      1/10/25 4:10:32 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Amado Rafael closing all direct ownership in the company (SEC Form 4)

      4 - Poseida Therapeutics, Inc. (0001661460) (Issuer)

      1/8/25 2:17:50 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Corning Luke closing all direct ownership in the company (SEC Form 4)

      4 - Poseida Therapeutics, Inc. (0001661460) (Issuer)

      1/8/25 2:17:02 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Financials

    Live finance-specific insights

    See more
    • Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

      Strong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target  Cash flow positive for the first nine months of 2024; $130 million generated in milestone and upfront payments to-date  Presented positive interim Phase 1 results for RMAT-designated P-BCMA-ALLO1 with 91% overall response rate and differentiated safety profile in heavily pretreated relapsed/refractory BCMA-exposed and BCMA-naïve multiple myeloma patients Introduced P-BCMACD19-ALLO1 as wholly-owned program with compelling biologic rationale for autoimmune disease and hematological malignancies On track to deliver further updates across allogeneic CAR-T

      11/7/24 4:05:00 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

      Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPRC5D-targeting treatment modality Differentiated P-BCMA-ALLO1 safety results with no dose-limiting toxicities, low rates of CRS and ICANS all Grade 2 or less and no graft vs. host disease or Parkinsonism P-BCMA-ALLO1 was recently granted Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and is being evaluated in a Phase 1/1b clinical trial in patients with relapsed/refractory multiple myeloma who have previously received three or more prior lines of therapy Company to host we

      9/27/24 4:30:00 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

      Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem cell memory T cell (TSCM) platform Company to host conference call on Saturday, September 28, 2024, at 1 PM ET / 10 AM PT to review the P-BCMA-ALLO1 Phase 1 IMS oral presentation data Poseida initiates P-BCMA-ALLO1 Phase 1b clinical trial in patients with multiple myeloma, generating $20 million payment from Roche SAN DIEGO, Sept. 5, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, announced today that

      9/5/24 9:00:00 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Poseida Therapeutics Inc.

      SC 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

      11/27/24 7:01:59 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Poseida Therapeutics Inc. (Amendment)

      SC 13G/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

      6/7/24 1:30:02 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Poseida Therapeutics Inc. (Amendment)

      SC 13G/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

      5/8/24 4:01:24 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Poseida Therapeutics Inc.

      15-12G - Poseida Therapeutics, Inc. (0001661460) (Filer)

      1/21/25 6:04:42 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Poseida Therapeutics Inc.

      SCHEDULE 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

      1/13/25 4:05:12 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Poseida Therapeutics Inc.

      EFFECT - Poseida Therapeutics, Inc. (0001661460) (Filer)

      1/13/25 12:15:09 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

      Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's Pharmaceuticals Division SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, auto

      11/26/24 1:10:00 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MaxCyte Appoints Cynthia Collins to its Board of Directors

      ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe

      10/15/24 8:05:00 AM ET
      $CERT
      $MXCT
      $PSTX
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care